Sarana Meditama Metropolitan Tbk PT
Sarana Meditama Metropolitan Tbk PT operates in the healthcare facilities and services industry, providing pharmaceuticals and related healthcare services.
Business. Sarana Meditama Metropolitan Tbk PT (SAME.JK) is a healthcare company engaged in pharmaceuticals and healthcare facilities and services. The firm operates within the Healthcare Services & Equipment sector, generating revenue through service-based models typical of the industry. Headquarters and specific operating segment details are not provided in the available data. The company is primarily listed on the Indonesia Stock Exchange (IDX) under the ticker SAME.JK.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Sarana Meditama Metropolitan Tbk PT (SAME.JK) is a healthcare company engaged in pharmaceuticals and healthcare facilities and services. The firm operates within the Healthcare Services & Equipment sector, generating revenue through service-based models typical of the industry. Headquarters and specific operating segment details are not provided in the available data. The company is primarily listed on the Indonesia Stock Exchange (IDX) under the ticker SAME.JK.
Sarana Meditama Metropolitan Tbk PT has a liquidity position that is characterized by a current ratio of 0.9, indicating that its current liabilities exceed its current assets. The company's cash and equivalents amount to 41,000,000,000, which is significantly lower than its long-term debt of 974,054,110,770, suggesting a potential liquidity risk. The return on equity is 0.0004, and the return on assets is 0.0003, both of which are very low, indicating that the company is not generating significant returns for its shareholders or assets.
The company's profitability is reflected in its net income of 14,304,565,000, but this is relatively small compared to its total revenue of 435,772,363,980. The operating income of 26,411,536,610 is also modest, and the gross profit of 146,508,345,500 suggests that the company is not achieving high margins. These metrics are below the industry norms, indicating that the company may be struggling to maintain competitive profitability.
The company's revenue is primarily concentrated in the healthcare sector, with no significant diversification across segments or geographic regions. This concentration could pose a risk if the healthcare sector experiences a downturn. The company's exposure to different geographic markets is not disclosed, but the lack of segment data suggests that it may not have a diversified revenue base.
The company's growth trajectory is uncertain, as there is no clear indication of future revenue growth. The capital expenditure of -78,015,705,100 indicates that the company is not investing heavily in new projects or infrastructure, which could limit its growth potential. The free cash flow is negative at -12,172,122,339.9999, suggesting that the company is not generating enough cash to fund its operations and investments.
The risk assessment indicates that the company has a medium liquidity risk and a low dilution risk. The key flag of net cash being negative after subtracting total debt highlights the company's financial vulnerability. The dilution potential is low, but the company's financial structure may require additional financing in the future, which could lead to dilution.
Recent events and filings do not provide specific details about the company's operations or financial performance. The analyst estimate for the last actual revenue is 952,082,110,000 IDR, which is significantly higher than the reported revenue, suggesting potential discrepancies or unverified data.
- The company has a low return on equity and assets, indicating poor profitability.
- The liquidity position is weak, with a current ratio below 1 and significant long-term debt.
- The company's revenue is not diversified, posing a risk if the healthcare sector declines.
- The capital expenditure is negative, suggesting a lack of investment in growth.
- The company's free cash flow is negative, indicating insufficient cash generation.
- **margin_outlook_rationale**: The company's gross profit margin is moderate, but the operating and net profit margins are low, indicating potential cost management issues.
- **rd_outlook_rationale**: There is no specific information provided about the company's research and development activities or their impact on future growth.
Bull / Bear case
Generated · model-assistedRevenue grew 10% annually over four years, demonstrating consistent top-line expansion despite volatile profitability trends.
Net income surged 153.8% year-over-year in 2019, indicating a significant recent improvement in bottom-line performance.
Cash conversion of 62.58% ranks best-in-class among peers, suggesting superior efficiency in generating cash from operations.
Debt-to-equity ratio of 0.27 is below the cohort median of 0.32, indicating a relatively conservative leverage position.
Dilution risk is assessed as low, providing reassurance to existing shareholders regarding potential equity value erosion.
Net margin of 0.33% is significantly below the cohort median of 4.15%, highlighting weak profitability relative to peers.
Return on equity of 0.04% trails the cohort median of 4.56%, indicating extremely poor capital efficiency.
Credit risk is flagged as high, signaling substantial potential for financial distress or default issues.
Capital expenditure intensity is in the bottom quartile, suggesting heavy investment requirements relative to revenue generation.
In focus — financials by report
Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 494.68B, +16,4% YoY; Operating income −38,4% YoY.
- ▍Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 494.68B, +16,4% YoY
- ▍Operating income −38,4% YoY
- ▍Net income −118,5% YoY
- ▍Free cash flow −402,6% YoY
- ▍Net margin -0.6%
Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 492.27B, +13,5% YoY; Operating income +79,7% YoY.
- ▍Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 492.27B, +13,5% YoY
- ▍Operating income +79,7% YoY
- ▍Net income +1 060,4% YoY
- ▍Free cash flow +163,9% YoY
- ▍Net margin 3.8%
Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 434.16B, +5,4% YoY; Operating income +23,1% YoY.
- ▍Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 434.16B, +5,4% YoY
- ▍Operating income +23,1% YoY
- ▍Net income +173,8% YoY
- ▍Free cash flow −476,1% YoY
- ▍Net margin 1.1%
Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 440.87B, +1,2% YoY; Operating income +15,7% YoY.
- ▍Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 440.87B, +1,2% YoY
- ▍Operating income +15,7% YoY
- ▍Net income +566,4% YoY
- ▍Free cash flow +221,0% YoY
- ▍Net margin 2.2%
Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 425.07B; Operating income UNKNOWN ERROR IN UNIVERSE PROCESSING 34.15B.
- ▍Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 425.07B
- ▍Operating income UNKNOWN ERROR IN UNIVERSE PROCESSING 34.15B
- ▍Net margin 3.6%
Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 433.64B; Operating income UNKNOWN ERROR IN UNIVERSE PROCESSING 22.16B.
- ▍Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 433.64B
- ▍Operating income UNKNOWN ERROR IN UNIVERSE PROCESSING 22.16B
- ▍Net margin 0.4%
Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 411.89B; Operating income UNKNOWN ERROR IN UNIVERSE PROCESSING 19.71B.
- ▍Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 411.89B
- ▍Operating income UNKNOWN ERROR IN UNIVERSE PROCESSING 19.71B
- ▍Net margin -1.6%
Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 1.86T, +9,1% YoY; Operating income +12,9% YoY.
- ▍Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 1.86T, +9,1% YoY
- ▍Operating income +12,9% YoY
- ▍Net income +153,8% YoY
- ▍Free cash flow −64,4% YoY
- ▍Net margin 1.6%
Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 1.71T, +11,4% YoY; Operating income +116,4% YoY.
- ▍Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 1.71T, +11,4% YoY
- ▍Operating income +116,4% YoY
- ▍Net income −3,3% YoY
- ▍Free cash flow +86,8% YoY
- ▍Net margin 0.7%
Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 1.53T, +9,9% YoY; Operating income +38,0% YoY.
- ▍Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 1.53T, +9,9% YoY
- ▍Operating income +38,0% YoY
- ▍Net income +181,8% YoY
- ▍Free cash flow −1 534,8% YoY
- ▍Net margin 0.8%
Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 1.39T, +9,6% YoY; Operating income −81,4% YoY.
- ▍Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 1.39T, +9,6% YoY
- ▍Operating income −81,4% YoY
- ▍Net income −97,0% YoY
- ▍Free cash flow −109,1% YoY
- ▍Net margin 0.3%
Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 1.27T; Operating income UNKNOWN ERROR IN UNIVERSE PROCESSING 184.13B.
- ▍Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 1.27T
- ▍Operating income UNKNOWN ERROR IN UNIVERSE PROCESSING 184.13B
- ▍Net margin 11.3%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Sarana Meditama Metropolitan Tbk PT Market data — financials · 2026-05-29
- Sarana Meditama Metropolitan Tbk PT Market data — analyst estimates · 2026-05-29